Sepsis is a medical emergency.
Every minute counts!

About Immunexpress

We are pioneering technology that analyzes the patient's immune system to rapidly detect sepsis.

Immunexpress' technology is leading a paradigm shift in sepsis diagnosis — it uses blood gene expression to quantify the patient's immune response to a pathogen, rather than the traditional approach which tries to find a causative pathogen.

Our mission is to develop diagnostic technologies to help clinicians and patients to fight this life-threatening disease.

More about us

AT LEAST 30 MILLION PEOPLE DIE WORLD WIDE FROM SEPSIS EACH YEAR

About Sepsis

Sepsis is caused by a patient’s overwhelming immune response to an infection and, if undetected or left untreated,
leads to tissue damage, organ failure, permanent disability and often death.

Sepsis happens when pathogens trigger an overwhelming immune response.

Around the world physicians struggle to rapidly and reliably identify sepsis due to the lack of adequate diagnostic tools.

Our Technology

Traditional tests produce clinically actionable results in 24-48 hours for 20% of all patients tested.
SeptiCyte® RAPID produces clinically actionable results in one hour for 100% of patients tested.

 

How Our Technology Works

SeptiCyte® RAPID is highlighted in this 10News First Brisbane interview.

Partnership

Accurate diagnosis of sepsis is time-critical to save lives.

We have developed the fully automated SeptiCyte® RAPID cartridge, compatible with the Biocartis Idylla™ platform, enabling the quantification and analysis of gene expression from whole blood to diagnose sepsis in suspected patients. With this technology, we aim to improve clinical and economic outcomes for patients and to benefit all key healthcare stakeholders: medical professionals and payers.

How Idylla Works

Biocartis’ sample-to-result Idylla™ platform

News

Immunexpress.com

Data Supporting SeptiCyte® RAPID Performance for COVID-19 Patient Triage Presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Immunexpress Collaborator

eccmid_lisbon_2022_bild_logo2

A commercial rapid host-response test in COVID-19 severity stratification and triage

Immunexpress.com

Immunexpress CEO To Present at the Virtual Biotech Showcase 2022